#### Check for updates

### OPEN ACCESS

EDITED BY Qin Zhao, Northwest A&F University, China

#### REVIEWED BY Guoqing Zhuang, Henan Agricultural University, China Gaopeng Hou, Washington University in St. Louis, United States

\*CORRESPONDENCE Aijian Qin aijian@yzu.edu.cn

SPECIALTY SECTION

This article was submitted to Virology, a section of the journal Frontiers in Microbiology

RECEIVED 28 September 2022 ACCEPTED 17 October 2022 PUBLISHED 02 November 2022

#### CITATION

Yin D, Geng R, Shao H, Ye J, Qian K, Chen H and Qin A (2022) Identification of novel linear epitopes in P72 protein of African swine fever virus recognized by monoclonal antibodies. *Front. Microbiol.* 13:1055820. doi: 10.3389/fmicb.2022.1055820

#### COPYRIGHT

© 2022 Yin, Geng, Shao, Ye, Qian, Chen and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

## Identification of novel linear epitopes in P72 protein of African swine fever virus recognized by monoclonal antibodies

Dan Yin<sup>1,2,3</sup>, Renhao Geng<sup>1,2,3</sup>, Hongxia Shao<sup>1,2,3</sup>, Jianqiang Ye<sup>1,2,3</sup>, Kun Qian<sup>1,2,3</sup>, Hongjun Chen<sup>4</sup> and Aijian Qin<sup>1,2,3</sup>\*

<sup>1</sup>The International Joint Laboratory for Cooperation in Agriculture and Agricultural Product Safety, Ministry of Education, Yangzhou University, Yangzhou, China, <sup>2</sup>Jiangsu Co-Innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, China, <sup>3</sup>Jiangsu Key Laboratory of Zoonosis, Yangzhou, China, <sup>4</sup>Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences (CAAS), Shanghai, China

African swine fever (ASF) is one of the highly contagious and lethal diseases among domestic pigs and wild boars. The capsid protein P72 of African swine fever virus (ASFV) is very important for the diagnosis and vaccine development. However, the epitope of the protein is not clear. In this study, capsid protein P72 was expressed in Sf9 cells along with its chaperone B602L. A total of ten monoclonal antibodies (mAbs) specific to P72 protein were developed by fusions between SP2/0 cells and spleen cells of mice immunized with the recombinant-P72&B602L proteins expressed in Sf9 cells. Four linear B cell epitopes <sup>31</sup>SNIKNVNKSY<sup>40</sup>, <sup>41</sup>GKPDP<sup>45</sup>, <sup>56</sup>HLVHFNAH<sup>63</sup> and <sup>185</sup>ERLYE<sup>189</sup> were identified. Biological information analysis illustrated that epitopes <sup>31</sup>SNIKNVNKSY<sup>40</sup>, <sup>41</sup>GKPDP<sup>45</sup> and <sup>185</sup>ERLYE<sup>189</sup> were highly conserved within different ASFV strains. These findings may lead to a better understanding of the antibody-antigen interaction and provide new insights into the vaccine research and serological diagnosis of ASF.

#### KEYWORDS

African swine fever virus, monoclonal antibodies, p72, B602L, epitope

### Introduction

African swine fever (ASF) is caused by African swine fever virus (ASFV), a highly complex, large, and enveloped DNA virus belonging to the genus Asfivirus, family Asfarviridae (Alonso et al., 2018). The disease is highly contagious and lethal, usually causing up to 100% mortality in domestic pigs, and is classified as a notifiable disease by the World Organization for Animal Health (OIE) (Galindo and Alonso, 2017; Zhao et al., 2019).

African swine fever virus has a complex structure with multiple membranes and protein layers (Revilla et al., 2018). The outmost protein coat of the virion is an icosahedral capsid, which is mainly assembled from the protein P72 encoded by virus gene B646L. The major capsid protein (MCP) P72 is the most important structural component of the virion, accounting for about one-third of the total weight of the virus particle, making it one of the major antigens detected in infected pigs (Kollnberger et al., 2002; Yang et al., 2021). One of ASF control strategies is the early detection for the infected pigs, preventing viral spread and prompting eradication in advance (Dixon et al., 2020). Currently, control strategies rely on nucleic acid, antigen and antibody detections. The MCP P72 is considered to be an ideal antigen for routine serologic diagnosis due to its immunogenicity and antigen stability (Kollnberger et al., 2002). However, this application is sometimes haltered by the insolubility of recombinant P72 protein due to possible conformation mis-presentation (Yu et al., 1996). Therefore, different strategies ought to be applied for the aim of producing more reliable P72 antigens and antibodies. Early studies showed that another protein, B602L, is required for the formation of the viral icosahedral capsid and increasing trypsin-resistant P72 output (Liu et al., 2019). B602L has been described as a molecular chaperone for the correct folding of the MCP P72 (Epifano et al., 2006).

The P72 protein contains conserved immunogenic regions, suggesting that the P72 protein can potentially be used as a target to develop ASFV P72 mAbs for the detection of a broad spectrum of ASFV. Epitope identification of P72 is a key step in epitope-driven subunit vaccine design and immunodiagnostic tests. Although anti-P72 mAbs have been successfully produced, corresponding epitopes are limited. A single conformational neutralizing epitope and 4 linear epitopes have been identified on P72, but information on the other antigenic regions (epitopes) is absent (Borca et al., 1994; Heimerman et al., 2018).

In this study, we developed recombinant baculoviruses that co-express ASFV P72 and B602L, enabling correct expression of the P72 protein. A panel of mAbs against P72 recombinant protein were generated, together with their corresponding core linear B cell epitopes. Also, P72 sequences from different ASFV strains were aligned to analyze their relative conservation. These findings will be valuable for the development of epitope-based diagnostic kits and prophylactic techniques for ASFV infection.

### Materials and methods

### Virus and cells

African green monkey cells MA-104, human embryonic kidney 293T (HEK293T) cells and myeloma cell line SP2/0 stored in our laboratory were maintained in Dulbecco's modified Eagle medium (DMEM) (Thermo Fisher Scientific, Massachusetts, USA) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Massachusetts, USA) in a humidified incubator with 5% CO2 at 37°C. The Spodoptera frugiperda insect cells (Sf9), stored in our laboratory, were cultured in Sf-900 II SFM medium (Gibco, USA) at 27°C. Cryopreservation of all cell lines were using CELLSAVING (New Cell & Molecular Biotech, China). The ASFV genome (GenBank accession number MH766894), ASFV-positive sera (Convalescent sera from surviving pigs naturally infected with ASFV) were kindly provided by professor Rongliang Hu (Institute of Changchun Veterinary Medicine, Jilin, China). The recombinant virus ASFVGZ∆MGF100-1R (The open reading frame of MGF100-1R was replaced by an EGFP expression cassette) was prepared in the previous study (Liu et al., 2021).

# Construction of recombinant P72 and B602L baculoviruses

The fragments of *B646L* (encoding P72) and *B602L* genes were amplified from the ASFV genome (GenBank accession number MH766894) with specific primers (**Supplementary Table 1**) and cloned into the baculovirus transfer vector pFastBac HTA to construct the recombinant P72 and B602L baculoviruses vectors, namely pFast-P72 and pFast-B602L, respectively. These two vectors encode the target proteins with hexa-histidine tag (His-tag). Subsequently, the constructs were transformed into *E. coli* DH5 $\alpha$  competent cells (Vazyme Biotech Co., Ltd., Nanjing, China), and confirmed by Sanger sequencing (Sangon Biotech, Shanghai, China).

According to Bac-to-Bac Expression System, the recombinant plasmids were transformed into DH10Bac *E. coli* cells to construct recombinant baculoviruses. The recombinant virus DNA, bacmid-P72 and bacmid-B602L, were extracted by alkaline process (Haberl et al., 2013). Then the recombinant virus DNA bacmid-P72 and/or bacmid-B602L were transfected into Sf9 cells. Five days post-infection, the supernatant and cells were collected for virus passage. After three passages of infection, the baculoviruses were harvested, and named as recombinant-P72 baculovirus, recombinant-B602L baculovirus and recombinant-P72&B602L baculovirus, respectively.

Sf9 cells were infected with recombinant-P72 baculovirus and/or recombinant-B602L baculovirus at 1-2 multiplicity of infections (MOI), or infected with recombinant-P72&B602L baculovirus at 2 MOI. 5 days post-infection, cells were fixed

with 60% acetone and subjected to immunofluorescence assays (IFA) with ASFV-positive sera and fluorescein isothiocyanateconjugated (FITC-conjugated) goat anti-swine IgG (Jackson, USA). Then, the expressed protein was also confirmed by western blotting with 6x-His Tag mAb (Thermo Fisher Scientific, USA) and horseradish peroxidase-conjugated (HRPconjugated) goat anti-mouse IgG (Jackson, USA) using the Super ECL Detection Reagent (Cat No. 36208; Yeasen, Shanghai, China). Universal antibody diluent was purchased from New Cell & Molecular Biotech (NCM, China).

# Production and characterization of monoclonal antibodies against P72 protein

Monoclonal antibodies against P72 protein were produced according to the previous method (Tesfagaber et al., 2021). Briefly, the recombinant-P72&B602L expression proteins were emulsified with complete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, USA) at a 1:1 ratio. 6-week-age BALB/c mice were immunized with 100  $\mu$ g of immunogen. Three booster immunizations were performed every two weeks with the same dosage of immunogen emulsified with incomplete Freund's adjuvant (Sigma-Aldrich, St. Louis, MO, USA). Three days post the fourth immunization, spleen cells were harvested and fused with SP2/0 cells. The hybridoma cells were selected in a hypoxanthine-aminopterin-thymidine (Sigma-Aldrich, St. Louis, MO, USA) and hypoxanthine-thymidine (Sigma-Aldrich, St. Louis, MO, USA) medium. The supernatants of hybridomas were screened for P72-specific antibodies by IFA on MA104 cells infected with ASFVGZAMGF100-1R, which was performed under biosecurity level 3 (BSL-3) conditions in the Spirit Jinyu Biological Pharmaceutical Co. LTD. (Liu et al., 2021). Rhodamine red-conjugated goat anti-mouse IgG (Jackson, USA) was used as the secondary antibody in IFA analysis. Positive clones were amplified and subcloned to produce monoclonal hybridoma cell lines and mAbs. Antibody subtypes were determined through the SBA Clonotyping System-HRP kit (Southern Biotech, Birmingham, USA) according to the manufacturer's instructions. The specificity of the mAbs against the recombinant protein and virions was evaluated using western blotting and IFA.

# Mapping of the linear B cell epitopes of P72 protein

Immunofluorescence assays and western blotting methods were used to identify the smallest epitope recognized by mAbs. The truncated *B646L* gene fragments were ligated into the vectors pCAGGS and transfected into 293T cells. A progressive procedure was adopted to identify the epitope recognized by each mAb, based on gradually shortened P72 truncated

fragments, which was confirmed by IFA. A total of 50 truncated fragments (P1-P8) were designed and screened, and the length and position of these truncated fragments of P72 were shown in **Figure 5**. According to IFA results, partial truncated fragments of P72 were ligated into pET-32a and transformed into *E. coli* BL21 (DE3) cells (Vazyme Biotech Co., Ltd., Nanjing, China) for expression. The minimal epitopes recognized by the mAbs were further verified by western blotting. All primers were synthesized by Sangon Biotech (Shanghai, China) and listed in **Supplementary Table 1**.

### **Biological information analysis**

The conservation analysis of the identified epitopes was implemented by Clustal W in MegAlign software, version 7.1.0 (DNAstar). The spatial distribution and the structure of the identified epitopes within P72 (PDB: 6L2T) were visualized by the PyMOL Molecular Graphics System (Version 2.4.0, Schrödinger, LLC.).

### Results

# B602L protein promotes the expression of P72 protein in Sf9 cells

To examine whether co-expression of P72 with B602L leads to an increase in the output of protein P72, Sf9 cells infected with recombinant baculoviruses expressing ASFV P72 and/or B602L were harvested 5 days post-infection. IFA results showed that Sf9 cells infected with only recombinant-P72 baculovirus or recombinant-B602L baculovirus generated poor signals, while those infected with recombinant-P72&B602L baculovirus or co-infected with both recombinant-P72 and recombinant-B602L baculoviruses displayed strongly with ASFV-positive sera (Figure 1A). At the same time, western blotting analysis was carried out with anti-His-tag mAb. The target protein reacted with the anti-His-tag mAb but not with the negative control. When P72 and B602L were expressed simultaneously in Sf9 cells, the expression level of P72 was significantly increased (P < 0.0001; Figures 1B,C). These results proved that coexpression of P72 and B602L contributed to the production and assembly of P72.

# Development of monoclonal antibodies against P72 protein

To produce anti-P72 mAbs, mice were immunized with the recombinant-P72&B602L proteins. 10 hybridoma cell lines producing antibodies to P72 were obtained, namely 6C10, 5F1, 4E2, 5H4, 2B12, 3H10, 7F10, 7C12, 7D1, and 3E6, respectively.



These mAbs belonged to two subtypes: IgG1 and IgG2a (Table 1). All the mAbs showed positive IFA reactions in HEK-293T cells co-transfected with pCAGGS-P72 and pCAGGS-B602L (Figure 2) as well as ASFVGZ $\Delta$ MGF100-1R infected MA104 cells (Figure 3). Notably, 3 mAbs (7F10, 7C12 and 7D1) showed negative IFA reactions in HEK-293T cells transfected with pCAGGS-P72 or pCAGGS-B602L alone (Table 1). This finding suggested that mAbs against novel epitopes of P72 can be obtained with the help of B602L. Results from western blotting showed that 4 mAbs (6C10, 5F1, 4E2 and 5H4) reacted strongly with the denatured P72 protein, suggesting that these mAbs recognized mainly linear epitopes (Figure 4). The IFA and western blotting reactions of the 10 mAbs are also listed in Table 1.

# Epitope mapping of anti-P72 monoclonal antibodies

To map the epitopes of 4 mAbs, 50 truncated P72 fragments expressed in HEK293T cells were used to investigate their

reactions with antibodies. The length and position of these truncated fragments in P72 are shown in Figures 5A,B. The results of 4 mAbs' reactivity were summarized in Supplementary Table 2. Next, the minimal linear epitopes were verified by western blotting. To determine the minimal residues of the linear B cell epitopes, the fragments P5-1-3-1 (1-42 aa), P5-1-3 (1-45 aa), P5-1-1 (1-63 aa), and P4-5 (1-189 aa) were further truncated from C-terminus by deleting amino acids one by one, and the fragments P6-1 (30-647 aa), P6-3 (40-647 aa), P7-1 (53-647 aa), and P8-2 (184-647 aa) were further truncated from N-terminus by deleting an amino acid one time. For P5-1-3-1, C-truncated fragments bound mAb 6C10 effectively until the <sup>40</sup>Tyr residue was removed (Figure 5C). For P6-1, N-truncated fragments bound 6C10 strongly until the <sup>31</sup>Ser residue was removed (Figure 5C). This indicated that peptide <sup>31</sup>SNIKNVNKSY<sup>40</sup> was the minimal residue. For P5-1-3 and P6-3, the binding capability of truncated fragments was completely lost when <sup>41</sup>Gly or <sup>45</sup>Pro was removed (Figure 5C), indicating that the minimal residue required by mAb 5F1 was <sup>41</sup>GKPDP<sup>45</sup>. For P5-1-1 and P7-1, the binding capability of truncated fragments was completely lost when <sup>56</sup>His or <sup>63</sup>His



The reactivity of monoclonal antibodies (mAbs) was analyzed with immunofluorescence assays (IFA). HEK-293T cells were co-transfected with the plasmids pCAGGS-P72 and pCAGGS-B602L. Cells were fixed and stained with anti-P72 mAbs (6C10, 5F1, 4E2, 5H4, 2B12, 3H10, 7F10, 7C12, 7D1, and 3E6) as the primary antibody and FITC-conjugated goat anti-mouse IgG as the secondary antibody. Following staining, all anti-P72 mAbs exhibited green fluorescence. NC was HEK 293T cells stained with cell supernatants from SP2/0 cells.

TABLE 1	Reactivity of monoclona	antibodies (mAbs) to African	swine fever virus (ASFV) P72 pro	otein.
---------	-------------------------	------------------------------	----------------------------------	--------

mAb	Isotype	ASFVGZAMGF100-1R infected MA104 cells		HEK-293T c with pCAGO pCAGGS	cells co-transfected GS-P72 and -B602L	HEK-293T cells transfected with pCAGGS-P72	HEK-293T cells transfected with pCAGGS-B602L	
		IFA	WB	IFA	WB	IFA	IFA	
6C10	lgG1- Kappa	+	+	+	+	+	_	
5F1	lgG1- Kappa	+	+	+	+	+	_	
4E2	lgG1- Kappa	+	+	+	+	+	-	
5H4	lgG1- Kappa	+	+	+	+	+	-	
2B12	lgG1- Kappa	+	_	+	_	+	_	
3H10	lgG1- Kappa	+	_	+	_	+	_	
7F10	lgG1- Kappa	+	_	+	_	_	_	
7C12	lgG1- Kappa	+	-	+	-	_	-	
7D1	IgG2a- Kappa	+	_	+	_	-	_	
3E6	IgG2a- Kappa	+	-	+	-	+	-	

(IFA) immunofluorescence assays; (WB) western blot; (+) positive; (-) negative.

was removed (Figure 5C), indicating that the minimal residue required by mAb 4E2 was <sup>56</sup>HLVHFNAH<sup>63</sup>. For P4-5, the mAb 5H4 effectively recognized the C-truncated fragments until the deletion of <sup>189</sup>Glu (Figure 5C). Moreover, the deletion of <sup>185</sup>Glu led to the loss of the immunoreactivity of the N-truncated fragments P8-2 (Figure 5C). The results indicated that the minimal residue required by mAb 5H4 was <sup>185</sup>ERLYE<sup>189</sup>. In summary, the 10-amino acid epitope (<sup>31</sup>SNIKNVNKSY<sup>40</sup>) for 6C10, the five-amino acid epitope (<sup>41</sup>GKPDP<sup>45</sup>) for 5F1, the nine-amino acid epitope (<sup>56</sup>HLVHFNAH<sup>63</sup>) for 4E2 and fiveamino acid epitope (185 ERLYE189) for 5H4 were minimally required for antibody-antigen interactions.



with anti-P72 mAbs (6C10, 5F1, 4E2, 5H4, 2B12, 3H10, 7F10, 7C12, 7D1, and 3E6) as indicated and stained with Rhodamine Red-conjugated goat anti-mouse IgG (red). Cell supernatant of SP2/0 was used as primary antibody in the NC group.



### Biological information analysis of the identified epitopes

To further analyze the conservation of the identified epitopes among different ASFV strains, sequences of 106 strains that represented the current status of epidemics worldwide were downloaded from GenBank, and their P72 sequences were aligned by MegAlign software. No amino acid substitutions and gaps were observed within <sup>31</sup>SNIKNVNKSY<sup>40</sup>, <sup>41</sup>GKPDP<sup>45</sup> and <sup>185</sup>ERLYE<sup>189</sup>, indicating that the three epitopes were highly conserved among ASFV prevailing strains (Figure 6). In the epitope <sup>56</sup>HLVHFNAH<sup>63</sup>, an amino acid substitution  $(L \rightarrow M)$  at position 57 was observed in multiple sequences. The result implied that the epitope <sup>56</sup>HLVHFNAH<sup>63</sup> might be less conserved than the other three epitopes. To understand the spatial distribution of the identified epitopes, the 3D



model of P72 (PDB: 6L2T) was used for further analysis. As shown in Figure 7, the linear epitope <sup>185</sup>ERLYE<sup>189</sup> is located in the middle of the trimer and the remaining three linear epitopes <sup>31</sup>SNIKNVNKSY<sup>40</sup>, <sup>41</sup>GKPDP<sup>45</sup> and <sup>56</sup>HLVHFNAH<sup>63</sup> are all located at the pseudo hexagonal base of the trimer.

### Discussion

In the past 100 years, ASF has emerged as a major threat to the global pig industry. Recently, ASF outbreaks in China, Southeast Asia and Belgium have created a sense of urgency to develop effective ways against ASF from entering negative

Majority	MASGGAFCLIANDGK	20	SNI KNVNKS	GKPD	EPTLSQIEE	THL VHE NAM	70 P	TCEYPO	JERLYE	90
R8 MH025916.1.seq						. M				
strain N10 MH025919.1.seq strain R25 MH025918.1.seq		***********	• • • • • • • • • • • •			M				
strain R35 MH025920.1.seq Tengani 62 AY261364 seg						. M	••••••			
Timor2019 1 MW396979.1.seq					•••••					
VNUA-ASFV-05L1.HaNam.VN.2020 MW465755.										
Warmbaths NC-044950.1.seq Warmbaths AY261365.1.seq										
Wuhan 2019-1 MN393476.1.seq Wuhan 2019-2 MN393477.1.seq										
Zaire MN630494.1.seq 19 WB-6905 MW306190.1 seq		· · · · · · · · · · · · · · ·	• • • • • • • • • • • •		• • • • • • • • • • •		•••••••			
26.Ss.2004 MN270977.1.seq										
47.5s.2008 NC_044955.1.seq										
56.Ca.1978 MN270969.1.seq 57.Ca.1979 MN270970.1.seq										
60.Nu.1997 MN270976.1.seq 85 Ca 1985 MN270973.1 seq							• • • • • • • • • • • • • • • • • • • •			
97.0L2012 MN270979.1.seq					• • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •			
140.Or.1985 MN270972.1.seq		· · · · · · · · · · · · · · · · · · ·								
141.Nu.1990 MN270974.1.seq 142.Nu.1995 MN270975.1.seq										
4996 WB MW723492.seq 22653.Ca.2014 MN270980.1.seq							• • • • • • • • • • • • • • • • • • •			
26544.OG10 KM102979.1.seq 26544.OG10 NC 044947.1.seq		· · · · · · · · · · · · · · · ·					• • • • • • • • • • • • • • • • • • • •			
47039 MW736597.seq										
Africa.tick AY578701.1.seq										
African swine fever virus NC_044942.1.s Arm.07.CBM.c4 LR881473.1.seq	***************	************								
ASFV.Kylv.2016.131 MN194591.1.seq ASFV.LT14.1490 MK628478.1.seq										
ASEV_HU_2018 MN715134.1.seq										
ASFV-wbShX01 MW033528.1.seq										
B53 MT956648.1.seq BA71V NC_001659.2.seq						M	• • • • • • • • • • • • • • • • • • •			
BA71V U18466.2.seq Belgium 2018.1 LR536725.1.seq										
Belgium.Etalle.wb.2018 MK543947.1.seq							• • • • • • • • • • • • • • • • • • • •			
Benin 97.1 AM712239.1.seq										
BUR.18.Rutana MW856067.1.seq Ca1978 2 MW723480.seq						M				
CADC_HN09 MZ614662.1.seq										
China.2018 AnhuiXCGQ MK128995.1.seq										
China.GD.2019 MW361944.1.seq CN.2019.InnerMongolia-AES01 MK940252.1.										
CzechRepublic 2017.1 LR722600.1.seq		·····	••••••							
E75 FN557520.1.seq										
E75 NC_044958.1.seq Estonia 2014 LS478113.1.seg										
Georgia 2007.1 FR682468.2.seq		••••• <mark>•</mark> ••••••			• • • • • • • • • • •					
Georgia 2008.1 MH910495.seq										
Germany 2020.1 LR899193.1.seq GZ201801 MT496893.1.seq										
Hanol_2019 MT166692.1.seq			••••••							
IND.AS.SD-02 2020 OL692743.1.seq							• • • • • • • • • • • • • • • • • • • •			
K49 MZ202520.1.seq Kabardino-Balkaria 19.WB-964 MT459800										
Ken.rie1 LR899131.1.seq Ken05 Tk1 NC 044945 1 seq			•••••••			M				
Ken05.Tk1 KM111294.1.seq						M				
Ken06.Bus KM111295.1.seq						M				
Kenya 1950 AY261360.1.seq Kenya 1950 NC-044944.1 seq				• • • • •		M				• •
L60 KM262844.1.seq										
Liv13.33 (OmLF2) MN913970.1.seq										
LO2018 MW647171.1.seq LO2018 MW647172.1.seq										• •
MAL 19.Karonga MW856068.seq										
Malawi Lil-20 1 AY261361.1.seq Mkuzi 1979 NC-044953.1.seq	*****************					M				
Moldova 2017.1 LR722599.seq NobeAp 2019 MT180393.1 seq		•••••	• • • • • • • • • • • •				• • • • • • • • • • • • • • • • • • •			• •
NHV NC_044943.1.seq										
NHV KM252845.1.seq Nu1979 MW723481.seq										
Nu1986 MW723482.1.seq		*******				• • • • • • • • •	• • • • • • • • • • • • • • • • • • • •			
Or_1984 MW800838.1.seq										
OURT 88 3 AM712240.seq OURT 88.3 NC_044957.1.seq										
Pig.Hellongjiang,HRB1.2020 MW656282.1. Pig.HLJ 2018 MK333180 1 seg							••••••			• •
Pol16_20186_07 MG939583.1.seq		· · · · · · · · · · · · · · · · · · ·					• • • • • • • • • • • • • • • • • • • •			
Pol17_03029_C201 MG939585.1.seq										
Pol17_04461_C210 MG939588.1.seq Pol17_31177_O81 MT847622.1.seq										
Pol17_55892_C754 MT847620.1.seq										
Pol19_53050_C1959.19 MT847623.2.seq										
Pretorisuskop.96.4 NC-044952.1.seq Pretoriuskop96 4 AY261363.1.seq	****************									
			L		-		,		·	

countries (Zhou et al., 2018; Garigliany et al., 2019; Nga et al., 2020). No antiviral drug is available to efficiently prevent or treat ASF nowadays. Due to the complex nature of the virus and many undefined features of ASFV immunobiology, developing effective ASF vaccines remain a challenge (Teklue et al., 2020). Epitope information about this virus is crucial because it is increasingly being used for the rational design of vaccines and to distinguish mAbs (Palatnik-de-Sousa et al., 2018). The P72

protein, which is critical in the formation of major components of the viral capsid, is involved in viral entry and plays an important role in the viral attachment (Gomez-Puertas et al., 1996). However, there is relatively little information on the exact epitope of P72. Here, we provided new insight into epitope mapping of P72 protein.

P72 is also a good candidate for antibody detection and considered to be one of the most immunogenic proteins



(Yu et al., 1996). According to previous studies, P72 was expressed as insoluble inclusion bodies in the E. coli expression system (Freije et al., 1993). Furthermore, Wan et al. have developed a colloidal-gold dual immunochromatographic strip with truncated P72 using the E. coli expression system (Wan et al., 2022). In addition, the truncated P72 is expressed independently in the baculovirus expression system for mAb production (Heimerman et al., 2018). It was demonstrated, however, that the p72 is unable to form trimers if expressed alone (Cobbold et al., 2001). In fact, the non-structural protein B602L has been described as a chaperone facilitating the correct folding of the p72 (Cobbold et al., 2001; Epifano et al., 2006). Previous studies have shown that only when P72 and B602L were co-expressed in HEK293F cells, correctly folded and assembled P72 can be obtained, and a highly specific colloidal gold immunochromatographic strip was developed based on this (Liu et al., 2019; Geng et al., 2022). The conformational misrepresentation of recombinant P72 protein may obscure some important epitopes and limit the production of mAbs. One advantage of the baculovirus system is the production of proteins with post-translational modifications. Therefore, we have created a new generation of recombinant baculoviruses that co-express ASFV P72 and B602L, thereby promoting the correct folding and assembly of the P72 protein. A significant increase in P72 expression was observed when P72 and B602L were co-expressed in Sf9 cells (Figure 1), consistent with the previous study in HEK293F cells (Liu et al., 2019). These findings may provide novel insights into ASFV vaccine development.

Next, 10 anti-P72 mAbs were developed based on recombinant baculoviruses co-expressing ASFV P72 and B602L. At the same time, 2 anti-B602L mAbs named 1F3 and 2E11

were also obtained in this experiment. And further studies on the characterization of anti-B602L mAbs are under process. Interestingly, 3 of the 10 anti-P72 mAbs in the IFA assay reacted well with HEK-293T cells co-transfected with pCAGGS-P72 and pCAGGS-B602L, but not with pCAGGS-P72 or pCAGGS-B602L transfected alone (**Table 1**). Therefore, in this study, three new anti-P72 mAbs (7F10, 7C12 and 7D1) recognized conformational epitopes of P72 protein that can be formed only in the presence of B602L. In addition, during the screening of mAbs against ASFV P72 protein, we found that mAbs with conformational epitopes had more dominance. These results suggested that B602L protein can assist the correct assembly and folding of P72 protein in Sf9 cells. Meanwhile, the chaperone B602L can help us screen mAbs against some important epitopes.

We found that four mAbs (6C10, 5F1, 4E2, and 5H4) reacted with denatured protein P72, indicating that these mAbs can be used for linear epitope identification. Epitopes are important factors in determining the antigenicity of viral structural proteins and influencing humoral immunity (Corral-Lugo et al., 2020). Identification of ASFV B-cell epitopes can help understand virus-host interactions and is essential for the development of diagnostic tools and vaccines. Currently, the molecular basis for P72 antigenicity remains largely unknown, and reports about antigenic epitopes of P72 are limited. In a previous study, a partial neutralizing mAb 135D4 was identified to recognize a conformational epitope on p72 between amino acid residues 400 and 404 (Borca et al., 1994). Subsequently, mAbs were prepared against a recombinant antigenic fragment, from amino acid (aa) 20-303, expressed in baculovirus, and four linear epitopes of P72 protein were identified (Heimerman et al., 2018). In the present study, IFA and western blotting were used to screen linear B-cell epitopes recognized by four mAbs against ASFV-P72. In order to determine the minimum linear epitope and key amino acid sites, we constructed shorter N- and C-truncated segments by deleting amino acids one by one and characterized by western blotting. To the best of our knowledge, we reported four new linear B cell epitope regions located on the P72 protein, namely <sup>31</sup>SNIKNVNKSY<sup>40</sup> recognized by 6C10, <sup>41</sup>GKPDP<sup>45</sup> recognized by 5F1, <sup>56</sup>HLVHFNAH<sup>63</sup> identified by 4E2 and <sup>185</sup>ERLYE<sup>189</sup> identified by 5H4.

African swine fever virus is an ancient evolutionary DNA virus with a wide range of genetic diversity and antigenic variability, which may affect the recognition of specific antigens in diagnosis and limit the effectiveness of ASFV vaccines (Malogolovkin and Kolbasov, 2019; Li et al., 2020). It is crucial for diagnostics and vaccines to select the conserved antigenic regions precisely. In this study, by comparing the P72 amino acid sequences from 106 ASFV isolates, we found that 3 out of 4 linear epitopes of P72 were completely conserved. In addition, location analysis indicated that all conserved linear epitopes were exposed on the surface of P72 protein, which may provide potential candidates for ASFV vaccine design and the development of diagnostic methods. The neutralization assays were performed on MA104 cell monolayers essentially as described previously (Gomez-Puertas and Escribano, 1997). As a result, none of the anti-P72 mAbs effectively neutralized ASFV (data not shown). The top of the P72 trimer is a propeller-like structure that extends to the outside of the virus (Wang et al., 2021), most likely the region where the neutralizing epitopes are located. However, none of the four linear epitopes identified in this experiment were at the top of the trimer, which can explain why these antibodies do not possess neutralizing activity. It also indicates that the neutralizing epitopes of the P72 protein are not the dominant epitopes.

In summary, we prepared anti-P72 mAbs based on recombinant baculoviruses co-expressing ASFV P72 and B602L. Three new anti-P72 mAbs were mapped, which can only recognize the conformational epitopes of P72 protein formed with the assistance of B602L. At the same time, four new linear B cell epitope regions located on the P72 protein were identified. Among them, epitopes <sup>31</sup>SNIKNVNKSY<sup>40</sup>, <sup>41</sup>GKPDP<sup>45</sup> and <sup>185</sup>ERLYE<sup>189</sup> were highly conserved among diverse ASFV strains. Aside from scientific significance for understanding the basis of antibody-antigen interaction, these findings may provide a solid foundation for further investigations into the antigenic functions of ASFV P72 protein, and the development of diagnostics and effective ASFV vaccines.

### Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

### **Ethics statement**

This animal study was reviewed and approved by Animal Care Committee of Yangzhou University in China.

### Author contributions

DY, RG, HS, JY, KQ, HC, and AQ performed to the material preparation, data collection, and analysis. DY wrote the first draft of the manuscript and revised by AQ. All authors contributed to the study conception, commented on previous versions of the manuscript, read and approved the final manuscript.

### Funding

This work was supported by National Science Foundation of China (Grant No. 31941016), the National Key Research and Development Program (Grant No. 2021YFD1800100), the Priority Academic Program Development of Jiangsu Higher Education Institutions, and the Jiangsu Co-innovation Center for the Prevention and Control of Important Animal Infectious Diseases and Zoonoses. The funding bodies did not play direct roles in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

### Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

### Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb. 2022.1055820/full#supplementary-material

#### 10.3389/fmicb.2022.1055820

### References

Alonso, C., Borca, M., Dixon, L., Revilla, Y., Rodriguez, F., Escribano, J. M., et al. (2018). ICTV virus taxonomy profile: Asfarviridae. *J. Gen. Virol.* 99, 613–614. doi: 10.1099/jgv.0.001049

Borca, M. V., Irusta, P., Carrillo, C., Afonso, C. L., Burrage, T., and Rock, D. L. (1994). African swine fever virus structural protein p72 contains a conformational neutralizing epitope. *Virology* 201, 413–418. doi: 10.1006/viro.1994.1311

Cobbold, C., Windsor, M., and Wileman, T. (2001). A virally encoded chaperone specialized for folding of the major capsid protein of African swine fever virus. *J. Virol.* 75, 7221–7229. doi: 10.1128/JVI.75.16.7221-7229.2001

Corral-Lugo, A., Lopez-Siles, M., Lopez, D., McConnell, M. J., and Martin-Galiano, A. J. (2020). Identification and analysis of unstructured, linear B-Cell epitopes in SARS-CoV-2 virion proteins for vaccine development. *Vaccines* 8:397. doi: 10.3390/vaccines8030397

Dixon, L. K., Stahl, K., Jori, F., Vial, L., and Pfeiffer, D. U. (2020). African swine fever epidemiology and control. *Annu. Rev. Anim. Biosci.* 8, 221–246. doi: 10.1146/annurev-animal-021419-083741

Epifano, C., Krijnse-Locker, J., Salas, M. L., Rodriguez, J. M., and Salas, J. (2006). The African swine fever virus nonstructural protein pB602L is required for formation of the icosahedral capsid of the virus particle. *J. Virol.* 80, 12260–12270. doi: 10.1128/JVI.01323-06

Freije, J. M., Munoz, M., Vinuela, E., and Lopez-Otin, C. (1993). High-level expression in *Escherichia coli* of the gene coding for the major structural protein (p72) of African swine fever virus. *Gene* 123, 259–262. doi: 10.1016/0378-1119(93) 90134-0

Galindo, I., and Alonso, C. (2017). African swine fever virus: A review. Viruses 9:103. doi: 10.3390/v9050103

Garigliany, M., Desmecht, D., Tignon, M., Cassart, D., Lesenfant, C., Paternostre, J., et al. (2019). Phylogeographic analysis of African swine fever virus, Western Europe, 2018. *Emerg. Infect. Dis.* 25, 184–186. doi: 10.3201/eid2501. 181535

Geng, R., Sun, Y., Li, R., Yang, J., Ma, H., Qiao, Z., et al. (2022). Development of a p72 trimer-based colloidal gold strip for detection of antibodies against African swine fever virus. *Appl. Microbiol. Biotechnol.* 106, 2703–2714. doi: 10. 1007/s00253-022-11851-z

Gomez-Puertas, P., and Escribano, J. M. (1997). Blocking antibodies inhibit complete African swine fever virus neutralization. *Virus Res.* 49, 115–122. doi: 10.1016/s0168-1702(97)01463-9

Gomez-Puertas, P., Rodriguez, F., Oviedo, J. M., Ramiro-Ibanez, F., Ruiz-Gonzalvo, F., Alonso, C., et al. (1996). Neutralizing antibodies to different proteins of African swine fever virus inhibit both virus attachment and internalization. *J. Virol.* 70, 5689–5694. doi: 10.1128/JVI.70.8.5689-5694.1996

Haberl, S., Jarc, M., Strancar, A., Peterka, M., Hodzic, D., and Miklavcic, D. (2013). Comparison of alkaline lysis with electroextraction and optimization of electric pulses to extract plasmid DNA from *Escherichia coli. J. Membr. Biol.* 246, 861–867. doi: 10.1007/s00232-013-9580-5

Heimerman, M. E., Murgia, M. V., Wu, P., Lowe, A. D., Jia, W., and Rowland, R. R. (2018). Linear epitopes in African swine fever virus p72 recognized by monoclonal antibodies prepared against baculovirus-expressed antigen. *J. Vet. Diagn. Investig.* 30, 406–412. doi: 10.1177/1040638717753966

Kollnberger, S. D., Gutierrez-Castaneda, B., Foster-Cuevas, M., Corteyn, A., and Parkhouse, R. M. E. (2002). Identification of the principal serological

immunodeterminants of African swine fever virus by screening a virus cDNA library with antibody. *J. Gen. Virol.* 83(Pt. 6), 1331–1342. doi: 10.1099/0022-1317-83-6-1331

Li, X., Xiao, K., Zhang, Z., Yang, J., Wang, R., Shen, X., et al. (2020). The recombination hot spots and genetic diversity of the genomes of African swine fever viruses. *J. Infect.* 80, 121–142. doi: 10.1016/j.jinf.2019.08.007

Liu, Q., Ma, B., Qian, N., Zhang, F., Tan, X., Lei, J., et al. (2019). Structure of the African swine fever virus major capsid protein p72. *Cell Res.* 29, 953–955. doi: 10.1038/s41422-019-0232-x

Liu, Y., Li, Y., Xie, Z., Ao, Q., Di, D., Yu, W., et al. (2021). Development and in vivo evaluation of MGF100-1R deletion mutant in an African swine fever virus Chinese strain. *Vet. Microbiol.* 261:109208. doi: 10.1016/j.vetmic.2021.109208

Malogolovkin, A., and Kolbasov, D. (2019). Genetic and antigenic diversity of African swine fever virus. *Virus Res.* 271:197673. doi: 10.1016/j.virusres.2019. 197673

Nga, B. T. T., Tran Anh Dao, B., Nguyen Thi L, Osaki, M., Kawashima, K., Song, D., et al. (2020). Clinical and pathological study of the first outbreak cases of African swine fever in Vietnam, 2019. *Front. Vet. Sci.* 7:392. doi: 10.3389/fvets. 2020.00392

Palatnik-de-Sousa, C. B., Soares, I. S., and Rosa, D. S. (2018). Editorial: Epitope discovery and synthetic vaccine design. *Front. Immunol.* 9:826. doi: 10.3389/fimmu.2018.00826

Revilla, Y., Perez-Nunez, D., and Richt, J. A. (2018). African swine fever virus biology and vaccine approaches. *Adv. Virus Res.* 100, 41–74. doi: 10.1016/bs.aivir. 2017.10.002

Teklue, T., Sun, Y., Abid, M., Luo, Y., and Qiu, H. J. (2020). Current status and evolving approaches to African swine fever vaccine development. *Transbound. Emerg. Dis.* 67, 529–542. doi: 10.1111/tbed.13364

Tesfagaber, W., Wang, L., Tsegay, G., Hagoss, Y. T., Zhang, Z., Zhang, J., et al. (2021). Characterization of Anti-p54 monoclonal antibodies and their potential use for African swine fever virus diagnosis. *Pathogens* 10:178. doi: 10.3390/pathogens10020178

Wan, Y., Shi, Z., Peng, G., Wang, L., Luo, J., Ru, Y., et al. (2022). Development and application of a colloidal-gold dual immunochromatography strip for detecting African swine fever virus antibodies. *Appl. Microbiol. Biotechnol.* 106, 799–810. doi: 10.1007/s00253-021-11706-z

Wang, G., Xie, M., Wu, W., and Chen, Z. (2021). Structures and functional diversities of ASFV proteins. *Viruses* 13:2124. doi: 10.3390/v13112124

Yang, B., Shi, Z., Ma, Y., Wang, L., Cao, L., Luo, J., et al. (2021). LAMP assay coupled with CRISPR/Cas12a system for portable detection of African swine fever virus. *Transbound. Emerg. Dis.* 69, e216–e223. doi: 10.1111/tbed.14285

Yu, M., Morrissy, C. J., and Westbury, H. A. (1996). Strong sequence conservation of African swine fever virus p72 protein provides the molecular basis for its antigenic stability. *Arch. Virol.* 141, 1795–1802. doi: 10.1007/BF01718302

Zhao, D., Liu, R., Zhang, X., Li, F., Wang, J., Zhang, J., et al. (2019). Replication and virulence in pigs of the first African swine fever virus isolated in China. *Emerg. Microbes Infect.* 8, 438–447. doi: 10.1080/22221751.2019.1590128

Zhou, X., Li, N., Luo, Y., Liu, Y., Miao, F., Chen, T., et al. (2018). Emergence of African swine fever in China, 2018. *Transbound. Emerg. Dis.* 65, 1482–1484. doi: 10.1111/tbed.12989